12th July 2021 saw the launch of the British Society of Pharmacy Sleep Services (BSPSS) bspss.org The Society will support through education, community pharmacists’ knowledge and understanding of various sleep disorders, to ensure that patients receive timely and appropriate advice and are signposted to other healthcare professionals where necessary. The BSPSS is undertaking research bspss.org…
Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis in Scotland
The Scottish Medicines Consortium recommends Novartis’ Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS) On July 12th 2021, Novartis announced that eligible patients in Scotland will soon have access to Kesimpta® (ofatumumab), the first self-administered, targeted B-cell therapy for patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical…
Pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for pridopidine for the treatment of ALS. Prilenia recently received a positive opinion from the Committee of Orphan Medicinal Products (COMP) in…
Organization for Human Brain Mapping: BrainArt
The Organization for Human Brain Mapping (OHBM) is an international society dedicated to fostering our understanding of brain organisation and function using neuroimaging techniques. Within the Society, various Special Interest Groups (SIGs) are dedicated to the promotion of shared interests, such as open science or trainees education. The annual OHBM competition highlights an ongoing aim…
William Wordsworth’s former Lake District home transformed into neurorehabilitation centre
Calvert Reconnections has today opened its doors – transforming the one-time Lake District home of poet William Wordsworth into a neurorehabilitation centre. It is located at Old Windebrowe, a Grade II listed Tithe barn on the outskirts of the bustling market town of Keswick in the Lake District. The centre is the UK’s first residential…
£165k boost for brain injury survivors in the Scottish Borders
A new service for brain injury survivors in the Scottish Borders has been launched following a £165,000 funding boost from the National Lottery Community Fund. Dynamic Community Fusion (DCF), a Galashiels-based social enterprise, has been awarded two years of funding to deliver the new Reconnect with Confidence programme for people living with brain injuries or…
Study to investigate the efficacy of opicapone in early-stage Parkinson’s disease (PD)
The design for a new phase III, double-blind, randomised trial for opicapone has been presented for the first time at the European Academy of Neurology (EAN) congress. Around 50% of patients with PD experience some degree of motor complications within 2–5 years of starting L-dopa/DDCI therapy and almost all develop such symptoms after 10 years…
Call for improved brain injury knowledge in social workers
UKABIF (UK Acquired Brain Injury Forum) is calling for social workers to be trained and informed around acquired brain injuries following a review into the death of a Brighton man. A review into the death of 42 year old ‘James’, who had an acquired brain injury (ABI), has found the current safeguarding system to be…
FDA Grants Accelerated Approval for Alzheimer’s Drug aducanumab
From www.fda.gov On June 8th, the US Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments. Accelerated approval can be based on…
